Kalydeco and Cystic Fibrosis
Approved as a treatment for cystic fibrosis, Kalydeco™ (ivacaftor) has been shown to improve lung function, reduce symptoms, and boost weight gain. Also, people who used this prescription medication during clinical trials had a reduced chance of pulmonary exacerbations. Kalydeco is approved for use in adults and children as young as six years old.
Kalydeco is prescribed for cystic fibrosis treatment in people with certain mutations, including G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R.
(Click Kalydeco Uses to learn more about using this drug to treat cystic fibrosis. This Web page offers detailed information on how Kalydeco works and other topics.)